Research
Hormonal
HbA1c decreased from 5.5 ± 0.3 at baseline to 5.3 ± 0.3 at 12 weeks and to 5.2 ± 0.027 at 24 weeks.
Practitioners can expect improvements in glycemic control in patients using compounded GLP-1 ± GIP agonists.
StrongSupportsmedium confidence
HbA1c decreased on average from 5.5 ± 0.3 at baseline to 5.3 ± 0.3 at 12 weeks ( p < 0.0001) and to 5.2 ± 0.027 ( p < 0.001) at 24 weeks.
Why this rating
Based on the retrospective cohort study design with a clear outcome measure.
Source
Real‐world observations of using compounded <scp>GLP</scp> ‐1 ± <scp>GIP</scp> agonists within a clinical pharmacist‐managed cardiometabolic clinic
Shannon W. Finks et al. · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · 2025
DOI 10.1002/jac5.2071
cohort · n=50Cited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →